GREENLAND MINES LTD Proceeds from Convertible Debt
GREENLAND MINES LTD (GRML) reported Proceeds from Convertible Debt of $2.15 million for the 12-month period ending 2025-12-31, per its 10-K/A filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-08-17
- GREENLAND MINES LTD proceeds from convertible debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- GREENLAND MINES LTD proceeds from convertible debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- GREENLAND MINES LTD proceeds from convertible debt for the quarter ending 2025-06-30 was $75.00K.
- GREENLAND MINES LTD proceeds from convertible debt for the quarter ending 2025-03-31 was $2.08M.
- GREENLAND MINES LTD proceeds from convertible debt for fiscal 2025 was $2.15M, a 3.51% increase from fiscal 2024.
- GREENLAND MINES LTD proceeds from convertible debt for fiscal 2024 was $2.08M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $75.00K derived: sum of 3 quarters · filed 2026-08-17 | $2.15M 10-K/A · filed 2026-08-14 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $75.00K derived: sum of 2 quarters · filed 2026-08-17 | $2.15M 10-Q · filed 2025-11-13 | $3.23M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $75.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | $2.15M 10-Q · filed 2026-08-17 | $3.23M derived: sum of 3 quarters · filed 2026-08-17 | $3.28M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $2.08M 10-Q/A · filed 2026-08-14 | $3.15M derived: sum of 2 quarters · filed 2026-08-14 | $3.20M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2024-12-31 | $1.08M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | $1.13M derived: sum of 2 quarters · filed 2026-08-14 | $2.08M 10-K/A · filed 2026-08-14 | |
| 2024-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.00M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $950.00K 10-Q · filed 2025-08-18 | |||
| 2023-03-31 | $510.00K 10-Q · filed 2024-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |